US lawmakers fault FDA for not pursuing "credible" heparin contamination leads
This article was originally published in Scrip
Executive Summary
In a letter to the US FDA's Commissioner Margaret Hamburg, members of the House energy and commerce committee have charged that the agency has not adequately followed up on "specific and credible" leads linking Chinese heparin firms to contaminated heparin in several different supply chains.